• Medidata outlined two oncology analyses scheduled for presentation at the ASCO 2026 Annual Meeting on June 1, 2026.
• One study linked breast cancer trial protocol choices to measurable shifts in patient enrollment and retention, flagging avoidable burdens that can deter participation.
• A separate pooled analysis supported tocilizumab as an effective option for many patients with CAR T-related cytokine release syndrome, while indicating a meaningful subset may need alternative rescue treatment.
• The findings position Medidata’s AI-driven protocol analytics and data-standardization approach as tools sponsors can use to de-risk trial execution and improve study performance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medidata Solutions Inc. published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.